We aim to establish a new class of medicines with the potential to engage intracellular targets that have previously been considered inaccessible and undruggable and make a meaningful difference in the lives of patients. Our team is united in its mission to treat devastating diseases and position Entrada to become the world's foremost intracellular therapeutics company.
Our proprietary Endosomal Escape Vehicle (EEV™) Platform has the potential to enable efficient intracellular delivery of specific and potent therapeutics to disease-causing targets previously considered inaccessible. Intracellular therapeutics have the potential to alter the treatment landscape for patients suffering from devastating diseases by targeting and engaging the underlying drivers of disease.
We are leveraging the power of our EEV™ Platform to create a diverse and expanding pipeline of oligonucleotide, antibody and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and metabolic diseases. Our lead program in Duchenne muscular dystrophy (DMD) has the potential to address a profound unmet need for patients and their families while offering what we believe is a path to advance additional EEV therapeutics for other diseases.